Another CRISPR approval not likely ' any time soon ' - report (NASDAQ:CRSP)

Following the recent FDA green light for the gene therapy Casgevy, "it is unlikely" that approval of a similar product will take place "any time soon," according to a report by GlobalData. According to GlobalData, only 24 CRISPR-based drugs are in Phase 2 trials, with 88% of such drugs in…#fda #globaldata #crispr #vrtx #jaspermorley #crisprtherapeutics #phase2 #aphase3 #crsp #ctx110
Source: Reuters: Health - Category: Consumer Health News Source Type: news